Overview
Portugal has developed a prominent cannabis cultivation and export sector, but domestic medical access operates through a defined pharmaceutical framework. Law 33/2018 established the legal basis for medicines, preparations and substances derived from cannabis for medicinal purposes, with INFARMED acting as the central competent authority for authorisation and oversight.
Legal basis and authority
Law 33/2018 created the framework for the medical use of cannabis-based medicines, preparations and substances. Decree-Law 8/2019 and subsequent INFARMED decisions provide implementation detail. The framework covers prescribing, dispensing, authorisation, cultivation, manufacture, wholesale distribution, import and export.
INFARMED is therefore the primary source for operational interpretation. Businesses should use current INFARMED forms, decisions and licensing guidance rather than relying solely on market summaries. Portuguese controlled-drug legislation and international narcotics obligations also remain relevant.
Authorisation routes
The legal route depends on whether the product is an authorised medicinal product or a cannabis-based preparation or substance supplied under the national framework. Cannabis preparations require marketing authorisation or the applicable national authorisation before supply. Product dossiers must demonstrate quality and provide the information required by INFARMED.
A cultivation licence does not create a right to place a product on the Portuguese market. Cultivation, manufacturing, import/export and commercial supply are distinct regulated activities. Scope, premises, responsible personnel, security and quality systems must match the authorised activity.
Prescription and pharmacy supply
Medical cannabis products are prescribed when conventional treatments are considered unsuitable or have not provided the expected effect, in accordance with the Portuguese framework and approved indications or conditions. Dispensing occurs through pharmacies under the applicable prescription and supply controls.
For market planning, the existence of domestic cultivation should not be confused with broad domestic consumption. Export-oriented production and Portuguese patient access are separate commercial pathways. Companies should assess authorised products, prescriber familiarity, pharmacy handling and reimbursement conditions.
GACP, GMP and product quality
Cultivation and collection controls should establish botanical identity, traceability, contamination prevention, pesticide control and consistent starting material. The revised EMA GACP guideline for herbal starting materials is relevant to the quality interface. Once activities constitute pharmaceutical manufacture, EU GMP expectations apply according to the operation and product stage.
Finished flower and preparations require controlled specifications, analytical methods, stability evidence, packaging controls and batch documentation. The European Pharmacopoeia Cannabis flower monograph provides a common official benchmark, but the authorised specification and INFARMED requirements remain decisive for the product.
Operational compliance
A robust Portuguese compliance plan maps every activity against the corresponding licence and responsible entity. It should identify which site cultivates, which site performs drying or extraction, who conducts testing, who releases batches, who holds the product authorisation and who manages export or domestic distribution.
The highest-risk failures occur at interfaces: unapproved subcontracting, activities performed outside licence scope, weak traceability between cultivation and batch records, and assumptions that export documentation is equivalent to domestic market authorisation. Periodic licence-scope review is therefore essential.
Implementation checklist
Before relying on this overview for a Portuguese market entry, confirm the current INFARMED licensing requirements directly with the authority, since guidance and processing timelines are subject to change. Verify GMP certification requirements for the specific product category, and confirm export documentation requirements if the product will also supply other EU markets.
Control framework
| Activity | Primary oversight | Key compliance focus |
|---|---|---|
| Cultivation | INFARMED and controlled-drug framework | Licence scope, security, traceability, GACP |
| Manufacture | INFARMED / EU GMP framework | Authorisation, GMP, validation, batch records |
| Product authorisation | INFARMED | Quality dossier, labelling, approved conditions |
| Import/export | INFARMED and narcotics controls | Permits, quantities, counterparties, reconciliation |
| Dispensing | Community pharmacy framework | Prescription, authorised product, patient information |
Practical sequence
References and primary guidance
- Portugal, Lei n.º 33/2018, de 18 de julho.
- Portugal, Decreto-Lei n.º 8/2019, de 15 de janeiro.
- INFARMED, Canábis para fins medicinais and associated deliberations.
- EMA, Guideline on good agricultural and collection practice for starting materials of herbal origin, Revision 1.
- European Pharmacopoeia monograph 3028: Cannabis flower.
References should be checked against the current consolidated legislation, pharmacopoeial edition and competent-authority guidance before operational use.
Frequently asked questions
Who regulates medical cannabis in Portugal?
INFARMED is the central competent authority for the principal licensing, product and oversight functions.
Does a cultivation licence permit domestic sales?
No. Cultivation authorisation is distinct from product authorisation and lawful domestic supply.
Can Portugal-grown cannabis be exported?
Yes, when the relevant cultivation, manufacturing, trade and import/export permissions are in place.
Is EU GMP required for every cultivation activity?
The applicable standard depends on the activity and stage; cultivation is generally managed through GACP principles, while pharmaceutical manufacturing steps fall under GMP.
Where are medical cannabis products dispensed?
They are supplied through pharmacies under the applicable prescription and authorised-product framework.
Related ECI reading
Educational content only. This page does not constitute medical, legal or regulatory advice.